PDF(Pubmed)
Abstract：
With the increase in life expectancy, aging has emerged as a significant health concern. Due to its various mechanisms of action, cardiometabolic drugs are often repurposed for other indications, including aging. This systematic review analyzed and highlighted the repositioning potential of cardiometabolic drugs to increase lifespan as an aging parameter in animal studies and supplemented by information from current clinical trial registries. Systematic searching in animal studies was performed based on PICO: \"animal,\" \"cardiometabolic drug,\" and \"lifespan.\" All clinical trial registries were also searched from the WHO International Clinical Trial Registry Platform (ICTRP). Analysis of 49 animal trials and 10 clinical trial registries show that various cardiovascular and metabolic drugs have the potential to target lifespan. Metformin, acarbose, and aspirin are the three most studied drugs in animal trials. Aspirin and acarbose are the promising ones, whereas metformin exhibits various results. In clinical trial registries, metformin, omega-3 fatty acid, acarbose, and atorvastatin are currently cardiometabolic drugs that are repurposed to target aging. Published clinical trial results show great potential for omega-3 and metformin in healthspan. Systematic Review Registration: crd.york.ac.uk/prospero/display_record.php?RecordID=457358, identifier: CRD42023457358.
摘要：
随着预期寿命的增加,衰老已经成为一个重要的健康问题。由于其各种作用机制，心脏代谢药物经常被用于其他适应症，包括衰老。本系统综述分析并强调了心脏代谢药物在动物研究中作为衰老参数增加寿命的重新定位潜力，并补充了当前临床试验注册中心的信息。基于PICO：“动物，“心脏代谢药物，\"和\"寿命。“所有临床试验注册中心也从世卫组织国际临床试验注册平台（ICTRP）检索。对49项动物试验和10项临床试验注册的分析表明，各种心血管和代谢药物具有靶向寿命的潜力。二甲双胍,阿卡波糖,阿司匹林是动物试验中研究最多的三种药物。阿司匹林和阿卡波糖是很有前途的,而二甲双胍表现出不同的结果。在临床试验登记处，二甲双胍,omega-3脂肪酸，阿卡波糖,阿托伐他汀和阿托伐他汀是目前用于靶向衰老的心脏代谢药物。已发表的临床试验结果显示了omega-3和二甲双胍在健康领域的巨大潜力。系统审查注册：crd。约克。AC.uk/prospro/display_record.php?RecordID=457358，标识符：CRD42023457358。
